| 摘要 |
<p>The discovery of plasmacytoid dendritic cell precurosors (PDC) as crucial effector cells with high production of type I interferon (IFNs) in early psoriasis development has led to the present invention that blocking of type I IFNs can be used for prevention and therapy of psoriasis. The invention relates to the use of a type I interferon clocking agent, such as a type I IFN antagonist (e.g. an anti-IFN-± antibody) or type I IFN receptor antagonist, for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.</p> |
